Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C97510
http://purl.obolibrary.org/obo/NCIT_C97510
|
|---|---|
| Preferred Name | Enoblituzumab |
| Definitions |
An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance. |
|---|---|
| label | Enoblituzumab
|
| prefLabel | Enoblituzumab
|
| in_subset |
See more
See less
|
| Preferred_Name | Enoblituzumab
|
| Is_Value_For_GDC_Property | |
| Display_Name | Enoblituzumab
|
| Maps_To | Enoblituzumab
|
| PDQ_Open_Trial_Search_ID | 703720
|
| Has_Target | |
| FDA_UNII_Code | M6030H73N9
|
| prefixIRI | NCIT:C97510
|
| NCI_Drug_Dictionary_ID | 703720
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C97510
|
| type | |
| PDQ_Closed_Trial_Search_ID | 703720
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| CAS_Registry | 1353485-38-7
|
| NCI_META_CUI | CL430254
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |